From LDL-C to Lp(a): A Multispecialty Approach to Reducing the Rising Tide of Cardiovascular Disease : Episode 17
Opinion
Video
CLEAR-Outcomes Data: Primary Prevention With Bempedoic Acid
Author(s):
Key Takeaways
- Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
- Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Panelists discuss how the CLEAR-outcomes trial demonstrated bempedoic acid’s efficacy in primary prevention of cardiovascular events, informing its clinical implementation for patients with statin intolerance or inadequate LDL-C control.
Video content above is prompted by the following:
- The primary prevention data with bempedoic acid from CLEAR-outcomes are exciting. Could you review the data and how you use BA in your practice?
Related Videos
Related Content
